Business Context and Reporting Period
Company: Pluri Inc. (Nasdaq: PLUR)
Filing Type: Form 8-K (Current Report)
Date of Report: May 28, 2024
Principal Executive Offices: Haifa, Israel
Context: The Company reported receiving a deficiency letter from Nasdaq regarding non-compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it identifies the following financial thresholds relevant to the listing deficiency:
- Stockholders' Equity Requirement: Minimum of $2,500,000 (Company is currently non-compliant).
- Alternative Standard 1: Market value of listed securities of at least $35 million (Company is currently non-compliant).
- Alternative Standard 2: Net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years (Company is currently non-compliant).
Material Changes and Listing Status
On May 28, 2024, Pluri Inc. received a deficiency letter from The Nasdaq Stock Market LLC stating it failed to satisfy Nasdaq Listing Rule 5550(b)(1). The Company is not in compliance with the Stockholders' Equity Requirement nor the alternative listing standards for market value or net income.
Current Trading Status: The non-compliance has no immediate effect on the listing or trading of the Company's common shares, which continue to trade on The Nasdaq Capital Market under the symbol "PLUR".
Outlook, Management Commentary, and Risks
Compliance Plan and Timeline
- Plan Submission: The Company has 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance.
- Extension: If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
- Delisting Risk: If the plan is not accepted or compliance is not achieved within the extension period, the Company may face delisting, though it retains the right to a hearing before an independent panel.
Management Commentary
Management intends to take all reasonable measures to regain compliance and remain listed on Nasdaq. However, the Company explicitly states there can be no assurance that Nasdaq will grant an extension or that the Company will ultimately regain compliance.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Specific risks cited include:
- Delays or obstacles in clinical trials.
- Failure of products to receive regulatory approval.
- Technology validation issues and scientific difficulties.
- Inability to retain key employees.
- Competition and pricing pressures.
- Patent insufficiency and potential product harm.
Investor Verification Checklist
- Verify the specific date by which the Company must submit its compliance plan (45 days from May 28, 2024).
- Monitor upcoming filings for the submission of the compliance plan and Nasdaq's acceptance thereof.
- Review the Company's most recent 10-K or 10-Q to confirm the exact stockholders' equity, market capitalization, and net income figures causing the deficiency.
- Assess the feasibility of the Company's proposed plan to raise equity or generate net income within the 180-day extension window.